AstraZeneca pulls cancer drug application in Europe

[September 21, 2016]  LONDON (Reuters) - AstraZeneca has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer because of late-stage questions raised by regulators reviewing the product.

However, the British company said on Wednesday that cediranib, a so-called VEGFR inhibitor, remained an important pipeline medicine and the decision did not affect its ongoing development in combination tests alongside other drugs.

(Reporting by Ben Hirschler; editing by Jason Neely)

[© 2016 Thomson Reuters. All rights reserved.]

Copyright 2016 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.